Two main factors have been implicated in the mechanism underlying the pathogenesis of acquired aplastic anemia: environmental factors and genetic susceptibility. Individuals vary in their ability to metabolize several DNA-damaging agents due to polymorphisms of biotransforming enzymes. Genetically determined differences in the expression of these enzymes could explain interindividual risks in developing acquired aplastic anemia. The aim of the study was to characterize the genetic polymorphism of biotransforming phase I (p450-cyp2E1) and phase II [microsomal epoxide hydrolase (mEh), glutathione Stransferase (GST)] enzymes in pediatric patients with acquired aplastic anemia. The GSTT1 null genotype (absence of both alleles) was associated with a significantly increased risk for acquired aplastic anemia (odds ratio, 2.8; 95% confidence interval, 0. 15-5.7) . In contrast, the GSTM1 null genotype or polymorphisms within the p450-cyp2E1 and mEh genes was not significantly different in patients and controls. Multivariate analysis was performed to assess whether the enzymes together or with other variables as age, gender, or response to therapy may have any significant association with the tested genotypes. In no combinations of the mentioned parameters was an association found with acquired aplastic anemia. GST are mainly involved in metabolizing hematotoxic and mutagenic substrates such as benzene derivatives. The GSTT1 null genotype may modulate the metabolism of exogenous pollutants or toxic intermediates. The absence of the GSTT1 enzyme, leading to genetic susceptibility toward certain pollutants, might determine the individual risk for development of acquired aplastic anemia in children. Abbreviations AA, acquired aplastic anemia CYP, cytochrome p450 GST, glutathione S-transferase MDS, myelodysplastic syndrome mEh, microsomal epoxide hydrolase NSAA, non-severe aplastic anemia SAA, severe aplastic anemia VSAA, very severe aplastic anemia
The common feature of AA is an empty bone marrow and pancytopenia in the peripheral blood (1, 2) . Although the causes for aplastic anemia are multiple, with the majority of cases remaining idiopathic, the pathogenic mechanism leading to the disease might be limited to two main pathways: environmental factors (3, 4) and genetic susceptibility (5, 6) . Environmental factors include viral infections (7, 8) , exposure to radiation (9), drugs (10), and chemicals (11) (12) (13) . They may cause DNA damage on the level of the hematopoietic progenitors (14) or lead to an activation of autologous immunologic mechanism (15) , also resulting in damage on the level of the hematopoietic progenitors (16 -18) . However, a history of a massive exposure to environmental pollutants will rarely be described in the history of a Caucasian child suffering from AA. Individuals vary in their ability to metabolize several DNA-damaging agents because of polymorphism of detoxify-ing enzymes. Variability in the expression or efficiency of these enzymes could explain interindividual risks for development of aplastic anemia in the presence of the above-mentioned environmental agents. Three of the most important biotransforming enzymes, CYP isoenzymes, mEh, and GST, show genetic polymorphisms. p450-cyp2E1 metabolizes a wide variety of drugs and chemicals, with preference for small molecules such as aldehydes, ketones, alcohols, and aromatic compounds (19) . A number of polymorphisms have been described in the p450-cyp2E1 gene (20) , with the PstI/RsaI polymorphism in the 5' flanking region being best defined (21) . The C2/C2 variant leads to an enhanced transcription of the (C2) p450-cyp2E1 gene, which increases enzyme activity compared with the C1/C1 variant (21) .
Among the phase II enzymes, mEh is involved in the first-pass metabolism of highly reactive epoxide intermediates and oxygen radicals. Two polymorphisms of mEH with a broad substrate spectrum (22, 23) have been found to be associated with susceptibility for several malignant diseases (24 -26) . The exon 3 point mutation T to C results in a tyrosine to histidine shift at position 113 (His 113), with a 50% reduced enzyme activity (slow allele), and the A to G transition leading to a histidine to arginine shift at position 139 (Arg 139), with a 25% faster enzyme activity (fast allele) (27, 28) .
GST represent a group of xenobiotic detoxifying enzymes (29, 30) , with GSTM (31-34), -T (35, 36), and -P (37) being polymorphs. A null genotype is characterized by the absence of the respective GST protein (38) . The GSTM1 null genotype has been shown to be associated with an increased risk of smoke-induced cancers (39 -41) , breast cancers (42) , and hepatocellular carcinoma (43, 44) . The GSTT1 null genotype has been shown to be associated with an increased risk for MDS (44 -46) . However, further studies on MDS have revealed conflicting results (44, (47) (48) (49) .
In this study, we analyzed three different enzymes in pediatric AA patients. p450-cyp2E1, mEh, and GST (M1 and T1) were chosen with regard to their substrate specificity, including hematotoxic and mutagenic DNA/damaging agents as aromatic compounds, radicals, and reactive oxygen.
PATIENTS AND METHODS

Patients.
The majority of patients suffering from AA were recruited between 1996 and 1999 through the pediatric cooperative multicenter study SAA-94, involving 37 centers in Germany and Austria. Some were tested independently from the study, as their diagnosis was before the beginning of the study. The diagnosis for AA was performed following the Camitta criteria and confirmed by bone marrow biopsy. Most of the patients suffered from VSAA (polymorphonuclear cells Ͻ200/L) or SAA (polymorphonuclear cells Ͻ500/L). Three patients had marked chromosomal abnormalities (ϩ19, Ϫ7, ϩ8) without morphologic signs of acute myeloid leukemia (AML) or MDS. Patients were ineligible if they showed clinical signs of paroxysmal nocturnal hematuria, Fanconi anemia, MDS, or congenital bone marrow failure disorders, or had undergone radiation, chemotherapy, or pretreatment with antilymphocyte globulin, cyclosporine A, or granulocyte colonystimulating factor. The patients' ages ranged between 1 and 16 y, with a median age of 9.6 y; 38 girls and 53 boys were analyzed. Details concerning the patients of the SAA-94 study, the treatment, and results are described by Fuhrer et al. (50) . The research protocol was approved by the ethics committee of the Ludwig-Maximilians University, Munich, and the Heinrich Heine University, Duesseldorf. Nonrandom controls were obtained from pediatric stem cell donors: four were siblings of patients suffering from solid tumors (one neuroblastoma, two non-Hodgkin's lymphoma, and one Hodgkin's lymphoma), four were siblings of patients suffering from X-linked severe combined immunodeficiency, one was a sibling of a patient suffering from adrenoleukodystropy, and six were siblings of patients diagnosed for relapsed acute leukemia. There was no increased incidence of cancer in the medical history of the families. The other donors were healthy Caucasian volunteers, whose samples were obtained from the blood bank. As all results obtained from controls' samples fit perfectly to the results from larger patient collectives, we believe that they are representative. The study has been approved by the ethics committee of the University of Munich as part of the SAA-94 study and by the ethics committee of the Heinrich Heine University, Duesseldorf. Informed consent was signed by the parents or the patients.
DNA isolation. DNA was prepared from whole blood or bone marrow specimens using the DNAeasy kit (QIAGEN, Hilden, Germany).
p450-cyp2E1 polymorphism. p450-cyp2E1 alleles were determined in 91 AA patients and 235 controls by their melting curve differences in a light cycler (Roche Molecular Biochemicals, Mannheim, Germany). Some controls were analyzed parallel to patients' samples. Other control data were established in the same laboratory by the same method in a separate research project. Approximately 100 ng of genomic DNA were used for each PCR reaction. The following primers were used: forward primer: 5' CCCGTGAGCCAGTCGAGT 3'; reverse primer: 5' CAGACCCTCTTCCACCTTCTAT 3' (5 M each); RsaI sensor: 5' CATAAAGATTCATTGTTAATATAAAAG-TACAAAATTX 3' (1.5 M); Rsa anchor: 5'-LCRes 540 The exon 4 polymorphism site was amplified with 5' GGGGT-GCCAGAGCCTGACCGT and 3' AACACGGGGCCCAC-CCTTGGC as described and digested with RsaI for 1 h at 37°C. The enzyme cuts the mutant allele, giving a 174-bp fragment, whereas the wild type shows a larger 295-bp band. The characteristic restriction products for exon 3 and exon 4 polymorphisms are depicted in Figure 1 .
GSTM1 and GSTT1 polymorphisms. To analyze the polymorphism of GSTM1 and -T1 genes, we developed a multiplex PCR detecting GSTM1 and -T1 as well as an internal ␤-globin control in a one-tube reaction. Samples from 78 patients and 122 controls were analyzed. Due to technical problems and high consumption of DNA, only 78 of 91 probes were analyzed. Briefly, GSTM1 was amplified using primers corresponding to the 3'-coding region of the human GST: 5' GAACTCCCTGAAAAGCTAAAG and 5' GTTGG-GAAATATACGGTG. Primers coding for the human GSTT1 were 5' TTCCTTACTGGTCCTCACATCTC and 5' TCAC-CGGATCATGGCCAGCA. The housekeeping gene ␤-globin was amplified using the primers 5' CAACTTCATCCACGT-TCACC and 5' GAAGAGCCAAGGACAGGTAC. The PCR reaction was carried out by heating to 94°C for 4 min, followed by 34 cycles of 1 min at 94°C, 60°C, and 72°C. A final run at 72°C for 7 min was included. To exclude systematic errors, 14 samples were analyzed repetitively. An example is given in Figure 2 .
Sensitivity of the PCR reaction was 8.6 ng/L DNA, as tested by stepwise dilution of GSTT1-and GSTM1-positive DNA. The PCR reaction was performed in the presence of 1 ng ␤-globin DNA as a standard control.
Statistics. Statistical analyses were performed using SPSS statistical software (version 7.5, SPSS Inc., Chicago, IL, U.S.A.). Significance was measured by Fisher's exact test (two-tailed), 2 test (two-tailed), and the Bonferoni method. Odds ratios (OR) were calculated and given within the 95% confidence interval (CI). Unconditional multivariate analysis was performed separately for each genotype. Age, gender, severity of acquired aplastic anemia, and therapeutic response were analyzed as co-variables for each locus and in combinations. Statistical analyses were performed with the help of the Institute for Statistics at the Heinrich Heine University, Duesseldorf.
RESULTS
p450-cyp2E1 polymorphism.
The frequency of the p450-cyp2E1 alleles is given in Table 1 . The prevalence for homozygosity of the rarer C2 was comparable in AA, with 0 of 91 (0%) analyzed samples and 1 of 235 (0.4%) controls with (OR, 1.6; 95% CI, 0.7-4.1; p Ͼ 0.28; NS). Heterozygous C1/C2 were found in 8 of 91 (9%) patients with AA and 12 of 235 P450-cyp2E1 polymorphisms were analyzed in children with acquired aplastic anemia in comparison with controls by their melting curve differences in a light cycler. The rarer C2 variant represents the Rsal restriction enzyme polymorphism and leads functionally to an enhanced enzyme activity. OR, odds ratio; CI, confidence interval.
(5.1%) controls (NS)
. The wild-type C1/C1 alleles were comparable in 83 of 91 (91%) patients with AA and 222 of 235 (94.5%) controls (NS). The respective prevalence in healthy controls was comparable to data from other studies that analyzed Caucasian patients (20, 21, 43) . These data exhibit no association of p450-cyp2E1 polymorphism with a risk for AA in children.
mEH polymorphism. The frequency of mEh polymorphism is given in Table 2 . The prevalence of the respective alleles in our controls was comparable to other studies (49) 2%) control samples (NS). The respective prevalence for each analyzed allele in healthy controls was comparable to data from other studies that analyzed Caucasian patients (45, 49, 51) . Transfer of the genotypes into putative phenotypes revealed no significant difference between the two alleles (Table  3) .
GST polymorphism. The frequencies of GSTT1 and GSTM1 alleles for all patients and their respective controls are given in Table 4 . The incidence of GSTT1 was significantly increased in AA cases compared with controls. Among the patients, 34 of 78 (39%) children were negative for the GSTT1 gene compared with 24 of 122 (20%) controls. We found a significantly increased risk for AA in children with a GSTT1 null genotype (OR, 2.8, 95% CI, 1.5-5.7; p Ͻ 0.004).
The GSTM1 null genotype occurred in 34 of 78 (44%) patients and in 66 of 122 (54%) controls (NS). The GSTM1 null genotype was not associated with an increased risk for AA. Nine of 78 patients (12%) and 3 of 122 controls (8%) were found to be negative for both GST alleles (NS). The prevalence in healthy controls was comparable to data from other studies that analyzed Caucasian patients.
Interaction among the genetic polymorphisms. To assess the combined effects of these polymorphisms, interactions between the GSTT1 null genotype and the other polymorphisms were analyzed by multivariate analysis. This analysis did not show a significant increase in the risk for developing AA for either of the tested interactions with the GSTT1 null genotype (data not shown).
Variables such as age or gender, the phenotype of the aplastic anemia (NSAA, SAA, and VSAA), response to immunosuppressive therapy, frequency of relapse, duration of the disease (data not shown), and development of a malignant disease (data not shown) were tested for correlation with either of the analyzed genotypes. However, none of these parameters showed a significant correlation.
DISCUSSION
Immunologic mechanisms and/or oxidative DNA damage are widespread means of induction in the pathogenesis of AA (41) . Bone marrow protection from xenobiotics depends on an With an odds ratio (OR) of 2.6, the risk for developing acquired aplastic anemia is significantly elevated for GSTT1 null genotype carrying children.
CI, confidence interval.
469
GST NULL GENOTYPE AND APLASTIC ANEMIA intact detoxification pathway. Individual differences in expression of biotransforming enzymes may lead to susceptibility to toxic agents. We analyzed genetic polymorphisms of biotransforming enzymes and correlated the data with the risk for AA. We found a significantly higher frequency of the GSTT1 null genotype among children with AA, whereas p450-cyp2E1, mEh, and GSTM1 were not correlated. However, the statistics show that GST may play a secondary role in the pathogenesis of AA in childhood. Viewing the literature, many factors have been associated with aplastic anemia, and the GSTT1 null genotype may be one risk factor among others. GSTT1 determines the ability to conjugate reactive components (44) such as monohalomethanes (52) and ethylene oxide (53, 54) and metabolism of low-molecular-weight-halogenated xenobiotics or reactive epoxides. GSTT1 is expressed in erythrocytes and lymphocytes (51, 52) and hence acts in the hematopoietic system. The importance of GSTT1 in the protection of hematopoietic cells from environmental pollutants has been proven in a population exposed to 1,3-butadiene-the in vitro sister chromatid exchange in human lymphocytes in the presence of 1,3-butadiene was 16-fold higher in cells from individuals lacking the GSTT1 gene expression (55, 56) . With regard to benzene detoxification, which is highly important in context with AA, GSTT1 is a major protection factor of individual susceptibility to benzene-induced chromosomal damage (51) and induces the urinary excretion of benzene metabolites with higher excretion of t,tMA (57) . Proving a direct causative coincidence between exogenous pollutants and marrow failure is difficult because the onset of marrow failure cannot be dated accurately. The delay in marrow disease after exposure to pollutants may be variable, and individuals with a genetic susceptibility due to an enzyme deficiency may be at greater risk than individuals with normal enzyme levels in the presence of environmental factors, even at low exposures. The GSTT1 null genotype may modulate the metabolism of exogenous pollutants or endogenous DNAdamaging processes. A genetic susceptibility toward certain pollutants might determine the individual risk against common levels of mutagenic pollutants.
